Serum metabolite profile can help identify individuals at risk of alcohol-related disease

NewsGuard 100/100 Score

A new study from the University of Eastern Finland is the first in the world to show that the serum metabolite profile can be used to identify individuals likely at risk of developing an alcohol-related disease in the future. The finding also opens up new avenues for preventing alcohol-related adverse effects. The study was published in Alcoholism: Clinical and Experimental Research.

Serum metabolite profile can help identify individuals at risk of alcohol-related disease

Alcohol is the cause underlying many severe diseases, such as alcohol dependence, liver cirrhosis and different types of cancer. It is estimated that alcohol accounts for approximately five per cent of the global burden of disease, and the WHO has listed the reduction of excessive consumption of alcohol as one of its most important priorities.

However, it is challenging to identify individuals most in need of an intervention, i.e., people who will go on to develop an alcohol-related disease."

Olli Kärkkäinen, Senior Researcher

The new study from the University of Eastern Finland discovered that changes in the serum metabolite profile are visible years before an individual is diagnosed with an alcohol-related disease. The researchers used metabolomics methods to analyze serum samples collected from middle-aged Finnish men in the 1980s as part of a prospective study focusing on risk factors of coronary artery disease. They analyzed baseline serum samples from individuals who were diagnosed with an alcohol-related disease in the course of a 30-year a follow-up.

On average, the diagnosis was made 13.6 years after the sample was taken. The study had two control groups: one group consisted of individuals whose consumption of alcohol at baseline was equally heavy, but who were not diagnosed with an alcohol-related disease later on. The other control group consisted of individuals whose consumption of alcohol at baseline was moderate, allowing the researchers to analyze alcohol-related changes.

There were significant differences in the groups' serum metabolite profiles. After controlling for self?reported alcohol use and gamma?glutamyl transferase levels, which is a biomarker of alcohol use, the researchers found that individuals who would later develop an alcohol-related disease had significantly lower serum levels of serotonin and asparagine than individuals in the control groups.

Serotonin is an important mediator that regulates the function of the nervous system, and lower levels of asparagine may be related to an increased risk of alcohol-induced organ damage."

Olli Kärkkäinen

Heavy alcohol use in itself was associated with considerable changes in the blood metabolite profile, e.g., in the levels of amino acids, steroid hormones and fatty acids.

"Our study is the first to show that the serum metabolite profile could be used to identify, already in advance, individuals who are likely to develop an alcohol-related disease in the future. This would have far-reaching consequences: if we can identify these individuals sufficiently early, we can target preventive measures at them. Successful prevention of alcohol-related adverse effects and diseases is highly significant both on the individual and societal levels," Senior Researcher Kärkkäinen says.

A limitation of the study is that it only analyzed middle-aged Finnish men who belonged to a risk group for alcohol-related diseases.

Future research should focus on analyzing whether these findings can be generalized to other population groups, including women, younger people and people who are not Finnish."

Olli Kärkkäinen

Source:
Journal reference:

Kärkkäinen, O., et al. (2020) Changes in circulating metabolome precede alcohol‐related diseases in middle‐aged men: a prospective population‐based study with a 30‐year follow‐up. Alcoholism: Clinical and Experimental Research. doi.org/10.1111/acer.14485.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Bidirectional Mendelian randomization uncovers link between plasma metabolites and heart attack risk